Monoclonal gammopathy of clinical and undetermined significance


  • Alissa Visram, MD Department of Medicine, University of Ottawa The Ottawa Hospital Research Institute, Ottawa, ON



Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant condition that arises when clonal B-lymphocytes or plasma cells secrete a monoclonal immunoglobulin protein (m-protein). To be diagnosed with MGUS, patients must have bone marrow clonal cell involvement of less than 10%, an m-protein concentration of <30 g/L, and no signs or symptoms related to the clonal proliferative process. 

Author Biography

Alissa Visram, MD, Department of Medicine, University of Ottawa The Ottawa Hospital Research Institute, Ottawa, ON

Dr. Alissa Visram is a hematologist at the Ottawa Hospital and an assistant professor within the Department of Medicine. She completed her hematology training at Dalhousie University in Nova Scotia, and her subspecialty clinical and research fellowship in plasma cell disorders at Mayo Clinic. Dr. Visram holds a Masters in Public Health and Epidemiology from Harvard University. She joined faculty in Ottawa in September of 2021 as a clinician investigator. Her clinical research is centered on understanding and improving health outcomes of patients with plasma cell disorders and developing cost-effective and efficacious immunotherapies for patients with multiple myeloma.


Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton III LJ. Prevalence of monoclonal gammopathy of undetermined significance. New England Journal of Medicine. 2006 Mar 30;354(13):1362-9.

Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-term follow-up of monoclonal gammopathy of undetermined significance. New England Journal of Medicine. 2018 Jan 18;378(3):241-9.

Kyle RA, Durie BG, Rajkumar SV, Landgren O, Bladé J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun;24(6):1121-7.

Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, Merlini G. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, The Journal of the American Society of Hematology. 2018 Oct 4;132(14):1478-85.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014 Nov 1;15(12):e538-48.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology. 2019 Jan;15(1):45-59.

Yadav P, Sathick IJ, Leung N, Brown EE, Cook M, Sanders PW, Cockwell P. Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study. Blood Cancer Journal. 2020 Mar 3;10(3):28.

Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. New England Journal of Medicine. 2021 May 20;384(20):1931-41.

Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy–associated peripheral neuropathy: diagnosis and management. InMayo Clinic Proceedings 2017 May 1 (Vol. 92, No. 5, pp. 838-850). Elsevier.

Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk–stratification, and management. American Journal of Hematology. 2019 Jul;94(7):812-27.

Le Cann M, Bouhour F, Viala K, Simon L, Tard C, Rossi C, Morel G, Lagrange E, Magy L, Créange A, Michaud M. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies. Blood. 2020 Nov 19;136(21):2428-36.

Gusdorf L, Asli B, Barbarot S, Néel A, Masseau A, Puéchal X, Gottenberg JE, Grateau G, Blanchard–Delaunay C, Rizzi R, Lifermann F. Schnitzler syndrome: validation and applicability of diagnostic criteria in real–life patients. Allergy. 2017 Feb;72(2):177-82.

Rongioletti F, Merlo G, Carli C, Cribier B, Metze D, Calonje E, Kempf W, Stefanato CM, Marinho E, Kanitakis J. Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases. Journal of the American Academy of Dermatology. 2016 Jun 1;74(6):1194-200.

Nelson CA, Zhong CS, Hashemi DA, Ashchyan HJ, Brown-Joel Z, Noe MH, Imadojemu S, Micheletti RG, Vleugels RA, Wanat KA, Rosenbach M. A multicenter cross-sectional study and systematic review of necrobiotic xanthogranuloma with proposed diagnostic criteria. JAMA Dermatology. 2020 Mar 1;156(3):270-9.

Sykes DB, O’Connell C, Schroyens W. The TEMPI syndrome. Blood, The Journal of the American Society of Hematology. 2020 Apr 9;135(15):1199-203.

Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: An update in 2019. Joint Bone Spine. 2019 Nov 1;86(6):707-13.

Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Advances in Therapy. 2015 Oct;32:920-8.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers. 2018 Oct 25;4(1):38..

Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine. 2017 Oct 3;49(7):545-51.

Vrana JA, Theis JD, Dasari S, Mereuta OM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kurtin PJ, Grogg KL, Dogan A. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014 Jul;99(7):1239.



How to Cite

Visram A. Monoclonal gammopathy of clinical and undetermined significance. Can Hematol Today [Internet]. 2023 Nov. 6 [cited 2024 Jul. 23];2(3):22-6. Available from: